Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy.

@article{Canini2015SeverityOL,
  title={Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy.},
  author={Laetitia Canini and Swati DebRoy and Zoe Mari{\~n}o and Jessica M. Conway and Gonzalo Crespo and Miquel Angel Navasa and Massimo D'Amato and P Ferenci and Scott J Cotler and Xavier Forns and Alan S. Perelson and Harel Dahari},
  journal={Antiviral therapy},
  year={2015},
  volume={20 2},
  pages={149-55}
}
BACKGROUND HCV kinetic analysis and modelling during antiviral therapy have not been performed in decompensated cirrhotic patients awaiting liver transplantation. Here, viral and host parameters were compared in three groups of patients treated with daily intravenous silibinin (SIL) monotherapy for 7 days according to the severity of their liver disease. METHODS Data were obtained from 25 patients, 12 non-cirrhotic, 8 with compensated cirrhosis and 5 with decompensated cirrhosis. The standard… CONTINUE READING